Base de dados : MEDLINE
Pesquisa : C04.557.470.200.025.305 [Categoria DeCS]
Referências encontradas : 4948 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 495 ir para página                         

  1 / 4948 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449064
[Au] Autor:Hou Y; Tozbikian G; Zynger DL; Li Z
[Ad] Endereço:From the Department of Pathology, The Ohio State University Wexner Medical Center, Columbus.
[Ti] Título:Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay).
[So] Source:Am J Clin Pathol;147(6):541-548, 2017 Jun 01.
[Is] ISSN:1943-7722
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives: This study aimed to compare a modified Magee equation with Oncotype DX (Genomic Health, Redwood City, CA) recurrence score (RS) and identify patients who are unlikely to benefit from Oncotype DX. Methods: Magee equation RS was calculated in 438 cases and correlated with Oncotype DX RS. Results: The Pearson correlation coefficient ( r ) for the Magee equation and Oncotype DX RS was 0.6645 ( P < .00001), and the overall agreement was 66.4%. All cases (11.6%) with a Magee equation RS greater than 30 or 11 or less had been correctly predicted to have either high Oncotype DX RS or low Oncotype DX RS, respectively. Conclusions: The modified Magee equation is able to identify up to 12% patients who are unlikely to benefit from Oncotype DX testing. Using the modified Magee equation RS on these patients would be an alternative to Oncotype DX, leading to cost savings.
[Mh] Termos MeSH primário: Adenocarcinoma Mucinoso/diagnóstico
Adenocarcinoma/diagnóstico
Biomarcadores Tumorais/genética
Neoplasias da Mama/diagnóstico
Carcinoma Ductal de Mama/diagnóstico
Carcinoma Lobular/diagnóstico
[Mh] Termos MeSH secundário: Adenocarcinoma/genética
Adenocarcinoma/patologia
Adenocarcinoma Mucinoso/genética
Adenocarcinoma Mucinoso/patologia
Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores Tumorais/metabolismo
Neoplasias da Mama/genética
Neoplasias da Mama/patologia
Carcinoma Ductal de Mama/genética
Carcinoma Ductal de Mama/patologia
Carcinoma Lobular/genética
Carcinoma Lobular/patologia
Feminino
Genômica
Seres Humanos
Meia-Idade
Técnicas de Diagnóstico Molecular/métodos
Medição de Risco
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE
[do] DOI:10.1093/ajcp/aqx008


  2 / 4948 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29351560
[Au] Autor:Vreemann S; Gubern-Mérida A; Borelli C; Bult P; Karssemeijer N; Mann RM
[Ad] Endereço:Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein 10, Nijmegen, the Netherlands.
[Ti] Título:The correlation of background parenchymal enhancement in the contralateral breast with patient and tumor characteristics of MRI-screen detected breast cancers.
[So] Source:PLoS One;13(1):e0191399, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Higher background parenchymal enhancement (BPE) could be used for stratification of MRI screening programs since it might be related to a higher breast cancer risk. Therefore, the purpose of this study is to correlate BPE to patient and tumor characteristics in women with unilateral MRI-screen detected breast cancer who participated in an intermediate and high risk screening program. As BPE in the affected breast may be difficult to discern from enhancing cancer, we assumed that BPE in the contralateral breast is a representative measure for BPE in women with unilateral breast cancer. MATERIALS AND METHODS: This retrospective study was approved by our local institutional board and a waiver for consent was granted. MR-examinations of women with unilateral breast cancers screen-detected on breast MRI were evaluated by two readers. BPE in the contralateral breast was rated according to BI-RADS. Univariate analyses were performed to study associations. Observer variability was computed. RESULTS: Analysis included 77 breast cancers in 76 patients (age: 48±9.8 years), including 62 invasive and 15 pure ductal carcinoma in-situ cases. A negative association between BPE and tumor grade (p≤0.016) and a positive association with progesterone status (p≤0.021) was found. The correlation was stronger when only considering invasive disease. Inter-reader agreement was substantial. CONCLUSION: Lower BPE in the contralateral breast in women with unilateral breast cancer might be associated to higher tumor grade and progesterone receptor negativity. Great care should be taken using BPE for stratification of patients to tailored screening programs.
[Mh] Termos MeSH primário: Neoplasias da Mama/diagnóstico por imagem
Imagem por Ressonância Magnética/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Mama/patologia
Neoplasias da Mama/genética
Neoplasias da Mama/patologia
Carcinoma Ductal de Mama/diagnóstico por imagem
Carcinoma Intraductal não Infiltrante/diagnóstico por imagem
Carcinoma Lobular/diagnóstico por imagem
Meios de Contraste
Detecção Precoce de Câncer
Feminino
Seres Humanos
Programas de Rastreamento
Meia-Idade
Mutação
Estudos Retrospectivos
Fatores de Risco
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Contrast Media)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180120
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191399


  3 / 4948 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29428039
[Au] Autor:Gusic LH; Walsh K; Flippo-Morton T; Sarantou T; Boselli D; White RL
[Ti] Título:Rationale for Mastectomy after Neoadjuvant Chemotherapy.
[So] Source:Am Surg;84(1):126-132, 2018 Jan 01.
[Is] ISSN:1555-9823
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Neoadjuvant chemotherapy (NAC) reduces tumor size, facilitating the use of breast conservation surgery (BCS). However, mastectomy remains the surgical outcome for certain women. The goal of this study was to determine the rationale for mastectomy after NAC, particularly in women eligible for BCS. Retrospective data were reviewed on patients who received NAC between February 2006 and August 2010 at our institution. Demographics and tumor characteristics were compared between patients who received BCS and mastectomy after NAC. Of 149 patients meeting inclusion criteria, 102 (68%) underwent BCS and 47 (32%) underwent mastectomy. Patient preference was the most common rationale for mastectomy (n = 19; 40%), followed by extent of disease (n = 13; 28%), presence of a breast cancer susceptibility gene (BRCA) mutation (n = 9; 19%), persistent positive margins (n = 5; 11%), and wound complications (n = 1; 2%). Of the 47 patients who underwent mastectomy, 37 (79%) were eligible for BCS after NAC. Larger pathologic tumor size (2.05 vs 1.25 cm, P = 0.04) and lobular histology [invasive lobular carcinomas, n = 12/17 (70%) vs invasive ductal carcinomas, n = 36/133 (27%); P < 0.01] were associated with increased rate of mastectomy. After NAC, patient preference, extent of disease, and the presence of a BRCA mutation account for the vast majority of mastectomies. Interestingly, most of these patients were shown to be candidates for breast conservation. This highlights the importance of educating patients about their surgical choice and the lack of evidence, showing a benefit to more extensive surgery.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Neoplasias da Mama
Carcinoma Ductal de Mama
Carcinoma Lobular
Tomada de Decisões
Mastectomia
Trastuzumab/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores Tumorais/sangue
Neoplasias da Mama/diagnóstico por imagem
Neoplasias da Mama/tratamento farmacológico
Neoplasias da Mama/genética
Neoplasias da Mama/cirurgia
Carcinoma Ductal de Mama/tratamento farmacológico
Carcinoma Ductal de Mama/genética
Carcinoma Ductal de Mama/cirurgia
Carcinoma Lobular/diagnóstico por imagem
Carcinoma Lobular/tratamento farmacológico
Carcinoma Lobular/genética
Carcinoma Lobular/cirurgia
Feminino
Seres Humanos
Mastectomia/métodos
Mastectomia Segmentar/métodos
Meia-Idade
Terapia Neoadjuvante/métodos
Invasividade Neoplásica
Estadiamento de Neoplasias
Educação de Pacientes como Assunto
Prognóstico
Estudos Retrospectivos
Medição de Risco
Fatores de Risco
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Biomarkers, Tumor); P188ANX8CK (Trastuzumab)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180212
[St] Status:MEDLINE


  4 / 4948 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29368824
[Au] Autor:Layne GP
[Ti] Título:Screening Mammography: Controversy and Recommendations.
[So] Source:W V Med J;112(6):26-9, 2016 Nov-Dec.
[Is] ISSN:0043-3284
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Neoplasias da Mama/diagnóstico
Carcinoma Lobular/diagnóstico
Mamografia
[Mh] Termos MeSH secundário: Adulto
Neoplasias da Mama/diagnóstico por imagem
Neoplasias da Mama/epidemiologia
Neoplasias da Mama/terapia
Carcinoma Lobular/diagnóstico por imagem
Carcinoma Lobular/epidemiologia
Carcinoma Lobular/terapia
Detecção Precoce de Câncer
Feminino
Guias como Assunto
Seres Humanos
Mamografia/métodos
Programas de Rastreamento/métodos
Meia-Idade
Valor Preditivo dos Testes
Prognóstico
Sensibilidade e Especificidade
Sociedades Médicas
Resultado do Tratamento
West Virginia/epidemiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE


  5 / 4948 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463158
[Au] Autor:Abrams MJ; Koffer PP; Wazer DE; Hepel JT
[Ad] Endereço:Department of Radiation Oncology, Tufts University School of Medicine, Tufts Medical Center, Boston, Massachusetts. Electronic address: mabrams@tuftsmedicalcenter.org.
[Ti] Título:Postmastectomy Radiation Therapy Is Associated With Improved Survival in Node-Positive Male Breast Cancer: A Population Analysis.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):384-391, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Because of its rarity, there are no randomized trials investigating postmastectomy radiation therapy (PMRT) in male breast cancer. This study retrospectively examines the impact of PMRT in male breast cancer patients in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. METHODS AND MATERIALS: The SEER database 8.3.2 was queried for men ages 20+ with a diagnosis of localized or regional nonmetastatic invasive ductal/lobular carcinoma from 1998 to 2013. Included patients were treated by modified radical mastectomy (MRM), with or without adjuvant external beam radiation. Univariate and multivariate analyses evaluated predictors for PMRT use after MRM. Kaplan-Meier overall survival (OS) curves of the entire cohort and a case-matched cohort were calculated and compared by the log-rank test. Cox regression was used for multivariate survival analyses. RESULTS: A total of 1933 patients were included in the unmatched cohort. There was no difference in 5-year OS between those who received PMRT and those who did not (78% vs 77%, respectively, P=.371); however, in the case-matched analysis, PMRT was associated with improved OS at 5 years (83% vs 54%, P<.001). On subset analysis of the unmatched cohort, PMRT was associated with improved OS in men with 1 to 3 positive nodes (5-year OS 79% vs 72% P=.05) and those with 4+ positive nodes (5-year OS 73% vs 53% P<.001). On multivariate analysis of the unmatched cohort, independent predictors for improved OS were use of PMRT: HR=0.551 (0.412-0.737) and estrogen receptor-positive disease: HR=0.577 (0.339-0.983). Predictors for a survival detriment were higher grade 3/4: HR=1.825 (1.105-3.015), larger tumor T2: HR=1.783 (1.357-2.342), T3/T4: HR=2.683 (1.809-3.978), higher N-stage: N1 HR=1.574 (1.184-2.091), N2/N3: HR=2.328 (1.684-3.218), black race: HR=1.689 (1.222-2.336), and older age 81+: HR=4.164 (1.497-11.582). CONCLUSIONS: There may be a survival benefit with the addition of PMRT for male breast cancer with node-positive disease.
[Mh] Termos MeSH primário: Neoplasias da Mama Masculina/mortalidade
Neoplasias da Mama Masculina/radioterapia
Carcinoma Ductal de Mama/mortalidade
Carcinoma Ductal de Mama/radioterapia
Carcinoma Lobular/mortalidade
Carcinoma Lobular/radioterapia
Linfonodos/patologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Análise de Variância
Neoplasias da Mama Masculina/patologia
Neoplasias da Mama Masculina/cirurgia
Carcinoma Ductal de Mama/patologia
Carcinoma Ductal de Mama/cirurgia
Carcinoma Lobular/patologia
Carcinoma Lobular/cirurgia
Terapia Combinada/métodos
Terapia Combinada/mortalidade
Seres Humanos
Estimativa de Kaplan-Meier
Masculino
Mastectomia Radical Modificada
Meia-Idade
Período Pós-Operatório
Radioterapia Adjuvante/mortalidade
Receptores Estrogênicos/análise
Receptores de Progesterona/análise
Estudos Retrospectivos
Programa de SEER
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Receptors, Estrogen); 0 (Receptors, Progesterone)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  6 / 4948 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29391091
[Au] Autor:Vora H; Kim S; Amersi F; Giuliano A; Chung A
[Ad] Endereço:Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
[Ti] Título:Lobular Carcinoma : A 15-Year Single Institution Review.
[So] Source:Am Surg;83(10):1040-1044, 2017 Oct 01.
[Is] ISSN:1555-9823
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The optimal management of lobular carcinoma In Situ (LCIS) has largely been debated. This study evaluated practice patterns and outcomes in women diagnosed with LCIS at a single institution from 2000 to 2014. Patient characteristics, histology, method of diagnosis, and management were examined in relation to disease-free survival, and overall survival (OS). A total of 209 patients were identified. Surgical management in the majority of patients was excisional biopsy or local excision. Patients diagnosed with LCIS by core biopsy were less likely to have mastectomy as compared with other methods of initial diagnosis (P = 0.01). A total of 108 (90.8%) patients received chemoprevention (CP) counseling, and 47 (43.5%) used chemoprevention. Estimated five-year disease-free survival rate was 96.3 per cent (95% confidence interval (CI): 92.0-98.3%) and OS rate was 98.6 per cent (95% CI: 94.6-99.7%). Older age was associated with a higher risk of subsequent breast cancer (hazard ratio (HR): 1.04; 95% CI: 1.01-1.07; P = 0.01). Older age (HR: 1.06; 95% CI: 1.02-1.11; P = 0.004) and diagnosis in the earlier years of the study period (HR: 0.65; 95% CI: 0.48-0.89; P = 0.007) were significantly associated with worse OS in multivariate analysis. LCIS has a favorable prognosis and is most commonly managed conservatively.
[Mh] Termos MeSH primário: Carcinoma de Mama in situ/diagnóstico
Carcinoma de Mama in situ/terapia
Neoplasias da Mama/diagnóstico
Neoplasias da Mama/terapia
Carcinoma Lobular/diagnóstico
Carcinoma Lobular/terapia
Padrões de Prática Médica/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adulto
Idoso
Antineoplásicos/uso terapêutico
Carcinoma de Mama in situ/mortalidade
Carcinoma de Mama in situ/patologia
Neoplasias da Mama/mortalidade
Neoplasias da Mama/patologia
Carcinoma Lobular/mortalidade
Carcinoma Lobular/patologia
Quimioprevenção
Terapia Combinada
Tratamento Conservador
Feminino
Seguimentos
Seres Humanos
Modelos Logísticos
Mastectomia
Meia-Idade
Prognóstico
Estudos Retrospectivos
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE


  7 / 4948 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29374745
[Au] Autor:Luczynska E; Niemiec J; Heinze S; Adamczyk A; Ambicka A; Marcyniuk P; Rudnicki W; Mitus JW; Dyczek S; Rys J; Sas-Korczynska B
[Ad] Endereço:Department of Radiology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Cracow, Poland.
[Ti] Título:Intensity and Pattern of Enhancement on CESM: Prognostic Significance and its Relation to Expression of Podoplanin in Tumor Stroma - A Preliminary Report.
[So] Source:Anticancer Res;38(2):1085-1095, 2018 02.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: It is possible that the degree of enhancement on contrast-enhanced spectral mammography (CESM), a new diagnostic method, might provide prognostic information for breast cancer patients. Therefore, in a group of 82 breast cancer patients, we analyzed the prognostic significance of degree and pattern of enhancement on CESM as well as its relation to: (a) breast cancer immunophenotype (based on ER/PR/HER2 status) (b) podoplanin expression in cancer stroma (lymphatic vessel density plus podoplanin-positivity of cancer-associated fibroblasts), and (c) other histological parameters. MATERIALS AND METHODS: For each tumor the intensity of enhancement on CESM was qualitatively assessed as strong or weak/medium, while the pattern - as homogenous and heterogenous. RESULTS: Herein we report, for the first time, that strong and heterogenous enhancement on CESM was related to unfavorable disease-free survival of breast cancer patients (p=0.005). Moreover, the strong enhancement was more frequent in large and node-positive tumors (pT>1, pN>0) (p=0.002), as well as in carcinomas with podoplanin-sparse stroma (p=0.008). CONCLUSION: Intensity and pattern of enhancement on CESM might provide (together with the results of other diagnostic imaging methods) not only the confirmation of presence or absence of tumor, but also prognostic information.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/metabolismo
Neoplasias da Mama/patologia
Meios de Contraste
Imagem por Ressonância Magnética/métodos
Glicoproteínas de Membrana/metabolismo
Células Estromais/metabolismo
[Mh] Termos MeSH secundário: Adenocarcinoma Mucinoso/metabolismo
Adenocarcinoma Mucinoso/patologia
Adenocarcinoma Mucinoso/terapia
Neoplasias da Mama/metabolismo
Neoplasias da Mama/terapia
Fibroblastos Associados a Câncer
Carcinoma Ductal de Mama/metabolismo
Carcinoma Ductal de Mama/patologia
Carcinoma Ductal de Mama/terapia
Carcinoma Lobular/metabolismo
Carcinoma Lobular/patologia
Carcinoma Lobular/terapia
Carcinoma Papilar/metabolismo
Carcinoma Papilar/patologia
Carcinoma Papilar/terapia
Terapia Combinada
Feminino
Seguimentos
Seres Humanos
Mamografia
Meia-Idade
Prognóstico
Estudos Retrospectivos
Células Estromais/patologia
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Contrast Media); 0 (Membrane Glycoproteins); 0 (PDPN protein, human)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  8 / 4948 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29202645
[Au] Autor:Ewertz M; Land LH; Dalton SO; Cronin-Fenton D; Jensen MB
[Ad] Endereço:a Department of Oncology , Odense University Hospital, Institute of Clinical Research, University of Southern Denmark , Denmark.
[Ti] Título:Influence of specific comorbidities on survival after early-stage breast cancer.
[So] Source:Acta Oncol;57(1):129-134, 2018 Jan.
[Is] ISSN:1651-226X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: While comorbidity indices are useful for describing trends in survival, information on specific comorbidities is needed for the clinician advising the individual breast cancer patient on her treatment. Here we present an analysis of overall survival, breast cancer-specific mortality, and effect of medical adjuvant treatment among breast cancer patients suffering from 12 major comorbidities compared with breast cancer patients without comorbidities. MATERIAL AND METHODS: The study population was identified from the Danish Breast Cancer Cooperative Group and included 59,673 women without prior cancer diagnosed with early-stage breast cancer in Denmark from 1990 to 2008 with an estimated median potential follow-up of 14 years and 10 months. Information on comorbidity and causes of death was derived from population-based registries. Multivariable proportional hazards regression models were used to assess the effect of comorbidities on mortality, all-cause and breast cancer specific, using patients without comorbidity as reference. RESULTS: At breast cancer diagnosis, 16% of patients had comorbidities and 84% did not. Compared with the latter, the risk of dying from all causes was significantly increased for all types of comorbidity, but the risk of dying from breast cancer was significantly increased only for peripheral vascular disease, dementia, chronic pulmonary disease, liver, and renal diseases. Comorbidities diagnosed within 5 years of breast cancer diagnosis correlated with a greater risk of dying than comorbidities diagnosed more than 5 years before breast cancer diagnosis. With a few exceptions, the effect of adjuvant treatment on breast cancer mortality was similar among patients with and without comorbidity. CONCLUSION: Breast cancer mortality was not significantly elevated for patients with prior myocardial infarction, congestive heart failure, cerebrovascular disease, connective tissue disease, ulcer disease, and diabetes. The similar effect of adjuvant treatment in patients with and without comorbidity underlines the importance of adhering to guideline therapy.
[Mh] Termos MeSH primário: Neoplasias da Mama/mortalidade
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Neoplasias da Mama/patologia
Carcinoma Ductal de Mama/mortalidade
Carcinoma Ductal de Mama/patologia
Carcinoma Lobular/mortalidade
Carcinoma Lobular/patologia
Estudos de Coortes
Comorbidade
Demência/mortalidade
Dinamarca/epidemiologia
Feminino
Seguimentos
Seres Humanos
Nefropatias/mortalidade
Hepatopatias/mortalidade
Pneumopatias/mortalidade
Meia-Idade
Doenças Vasculares Periféricas/mortalidade
Sistema de Registros
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE
[do] DOI:10.1080/0284186X.2017.1407496


  9 / 4948 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29202611
[Au] Autor:Lykkesfeldt AE; Iversen BR; Jensen MB; Ejlertsen B; Giobbie-Hurder A; Reiter BE; Kirkegaard T; Rasmussen BB
[Ad] Endereço:a Unit of Cell Death and Metabolism , Danish Cancer Society Research Center , Copenhagen , Denmark.
[Ti] Título:Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer.
[So] Source:Acta Oncol;57(1):67-73, 2018 Jan.
[Is] ISSN:1651-226X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cell culture studies have disclosed that the mitotic Aurora kinase A is causally involved in both tamoxifen and aromatase inhibitor resistant cell growth and thus may be a potential new marker for endocrine resistance in the clinical setting. MATERIAL AND METHODS: Archival tumor tissue was available from 1323 Danish patients with estrogen receptor (ER) positive primary breast cancer, who participated in the Breast International Group (BIG) 1-98 trial, comparing treatment with tamoxifen and letrozole and both in a sequence. The expression of Aurora A was determined by immunohistochemistry in 980 tumors and semi quantitively scored into three groups; negative/weak, moderate and high. The Aurora A expression levels were compared to other clinico-pathological parameters and outcome, defined as disease-free survival (DFS) and overall survival (OS). RESULTS: High expression of Aurora A was found in 26.9% of patients and moderate in 57.0%. High expression was significantly associated with high malignancy grade and HER2 amplification. High Aurora A expression was significantly more frequent in ductal compared to lobular carcinomas. We found no significant association between Aurora A expression and DFS or OS and no evidence of interaction between Aurora A expression and benefits from tamoxifen versus letrozole. CONCLUSIONS: Aurora A expression in breast tumors was associated with high malignancy grade III and with HER2 amplification. A trend as a prognostic factor for OS was found in patients with high Aurora A expression. No predictive property was observed in this study with early breast cancer.
[Mh] Termos MeSH primário: Aurora Quinase A/metabolismo
Neoplasias da Mama/metabolismo
Neoplasias da Mama/mortalidade
Resistência a Medicamentos Antineoplásicos
Receptores Estrogênicos/metabolismo
[Mh] Termos MeSH secundário: Antineoplásicos Hormonais/uso terapêutico
Inibidores da Aromatase/uso terapêutico
Biomarcadores/metabolismo
Neoplasias da Mama/patologia
Neoplasias da Mama/terapia
Carcinoma Ductal de Mama/metabolismo
Carcinoma Ductal de Mama/mortalidade
Carcinoma Ductal de Mama/patologia
Carcinoma Ductal de Mama/terapia
Carcinoma Lobular/metabolismo
Carcinoma Lobular/mortalidade
Carcinoma Lobular/patologia
Carcinoma Lobular/terapia
Dinamarca/epidemiologia
Intervalo Livre de Doença
Feminino
Seres Humanos
Imuno-Histoquímica
Nitrilos/uso terapêutico
Prognóstico
Receptor ErbB-2/metabolismo
Tamoxifeno/uso terapêutico
Triazóis/uso terapêutico
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antineoplastic Agents, Hormonal); 0 (Aromatase Inhibitors); 0 (Biomarkers); 0 (Nitriles); 0 (Receptors, Estrogen); 0 (Triazoles); 094ZI81Y45 (Tamoxifen); 7LKK855W8I (letrozole); EC 2.7.10.1 (ERBB2 protein, human); EC 2.7.10.1 (Receptor, ErbB-2); EC 2.7.11.1 (Aurora Kinase A)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE
[do] DOI:10.1080/0284186X.2017.1404126


  10 / 4948 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29202620
[Au] Autor:Tramm T; Kyndi M; Sørensen FB; Overgaard J; Alsner J
[Ad] Endereço:a Department of Pathology , Aarhus University Hospital , Aarhus , Denmark.
[Ti] Título:Influence of intra-tumoral heterogeneity on the evaluation of BCL2, E-cadherin, EGFR, EMMPRIN, and Ki-67 expression in tissue microarrays from breast cancer.
[So] Source:Acta Oncol;57(1):102-106, 2018 Jan.
[Is] ISSN:1651-226X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The influence of intra-tumoral heterogeneity on the evaluation of immunohistochemical (IHC) biomarker expression may affect the analytical validity of new biomarkers substantially and hence compromise the clinical utility. The aim of this study was to examine the influence of intra-tumoral heterogeneity as well as inter-observer variability on the evaluation of various IHC markers with potential prognostic impact in breast cancer (BCL2, E-cadherin, EGFR, EMMPRIN and Ki-67). MATERIAL AND METHODS: From each of 27 breast cancer patients, two tumor-containing paraffin blocks were chosen. Intra-tumoral heterogeneity was evaluated (1) within a single tumor-containing paraffin block ('intra-block agreement') by comparing information from a central, a peripheral tissue microarray (TMA) core and a whole slide section (WS), (2) between two different tumor-containing blocks from the same primary tumor ('inter-block agreement') by comparing information from TMA cores (central/peripheral) and WS. IHC markers on WS and TMA cores were evaluated by two observers independently, and agreements were estimated by Kappa statistics. RESULTS: For BCL2, E-cadherin and EGFR, an almost perfect intra- and inter-block agreement was found. EMMPRIN and Ki-67 showed a more heterogeneous expression with moderate to substantial intra-block agreements. For both stainings, there was a moderate inter-block agreement that improved slightly for EMMPRIN, when using WS instead of TMA cores. Inter-observer agreements were found to be almost perfect for BCL2, E-cadherin and EGFR (WS: κ > 0.82, TMAs: κ > 0.90), substantial for EMMPRIN (κ > 0.63), but only fair to moderate for Ki-67 (WS: κ = 0.54, TMAs: κ = 0.33). CONCLUSIONS: BCL2, E-cadherin and EGFR were found to be homogeneously expressed, whereas EMMPRIN and Ki-67 showed a more pronounced degree of intra-tumoral heterogeneity. The results emphasize the importance of securing the analytical validity of new biomarkers by examining the intra-tumoral heterogeneity of immunohistochemical stainings applied to TMA cores individually in each type of cancer.
[Mh] Termos MeSH primário: Neoplasias da Mama/metabolismo
[Mh] Termos MeSH secundário: Basigina/metabolismo
Biomarcadores Tumorais/metabolismo
Caderinas/metabolismo
Carcinoma Ductal de Mama/metabolismo
Carcinoma Lobular/metabolismo
Feminino
Seres Humanos
Imuno-Histoquímica
Antígeno Ki-67/metabolismo
Proteínas Proto-Oncogênicas c-bcl-2/metabolismo
Receptor do Fator de Crescimento Epidérmico/metabolismo
Análise Serial de Tecidos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (BCL2 protein, human); 0 (BSG protein, human); 0 (Biomarkers, Tumor); 0 (CDH1 protein, human); 0 (Cadherins); 0 (Ki-67 Antigen); 0 (Proto-Oncogene Proteins c-bcl-2); 136894-56-9 (Basigin); EC 2.7.10.1 (EGFR protein, human); EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE
[do] DOI:10.1080/0284186X.2017.1404128



página 1 de 495 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde